Skip to main content

Calcifediol supplementation in adults on hemodialysis: a randomized controlled trial

Abstract

Background

Vitamin D deficiency is associated with increased risks of mortality in people with chronic kidney disease. The benefits and harm of vitamin D supplementation on cardiovascular outcomes and mortality are unknown. We aimed to assess the effectiveness of calcifediol in reducing mortality in patients with vitamin D insufficiency on hemodialysis compared to no additional therapy.

Methods

A phase III, multicenter, randomized, open-label trial was conducted including 284 adults with vitamin D insufficiency undergoing hemodialysis who were randomly assigned to receive oral calcifediol or standard care for 24 months.

Results

Two hundred eighty-four participants were enrolled (143 assigned to the calcifediol group and 141 to the no additional therapy group). The primary outcome (mortality) occurred in 34 and 31 participants in the calcifediol and control group, respectively [hazard ratio (HR) 1.03; 95% confidence interval (CI) 0.63–1.67]. Calcifediol had no detectable effects on cardiovascular death (HR 1.06; 95% CI 0.41–2.74), non-cardiovascular death (HR 1.13; 95% CI 0.62–2.04), nonfatal myocardial infarction (HR 0.20; 95% CI 0.02–1.67) or nonfatal stroke (HR could not be estimated). The incidence of hypercalcemia and hyperphosphatemia was similar between groups. None of the participants underwent parathyroidectomy.

Conclusions

In adults treated with hemodialysis and who had vitamin D insufficiency, calcifediol supplementation for 24 months had inconclusive effects on mortality and cardiovascular outcomes.

Trial registration number

NCT01457001

Graphic abstract

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

Data availability statement

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request. Authors confirmed that the results presented in this paper have not been published previously in whole or part, except in abstract format.

Code availability

Not applicable.

References

  1. LaClair RE, Hellman RN, Karp SL et al (2005) Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 45(6):1026–1033

    Article  CAS  Google Scholar 

  2. Barreto DV, Barreto FC, Liabeuf S et al (2009) Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 4(6):1128–1135

    Article  CAS  Google Scholar 

  3. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF (2007) Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 147(12):840–853

    Article  Google Scholar 

  4. Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E (1988) Extra-renal production of calcitriol in chronic renal failure. Kidney Int 34(3):368–375

    Article  CAS  Google Scholar 

  5. Kandula P, Dobre M, Schold JD, Schreiber MJ Jr, Mehrotra R, Navaneethan SD (2011) Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 6(1):50–62

    Article  CAS  Google Scholar 

  6. Hewitt NA, O’Connor AA, O’Shaughnessy DV, Elder GJ (2013) Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. Clin J Am Soc Nephrol 8(7):1143–1149

    Article  CAS  Google Scholar 

  7. Kumar V, Yadav AK, Lal A et al (2017) A randomized trial of vitamin D supplementation on vascular function in CKD. J Am Soc Nephrol 28(10):3100–3108

    Article  CAS  Google Scholar 

  8. Galassi A, Bellasi A, Auricchio S, Papagni S, Cozzolino M (2013) Which vitamin D in CKD-MBD? The time of burning questions. Biomed Res Int 2013:864012

    Article  Google Scholar 

  9. Cardoso MP, Pereira LAL (2019) Native vitamin D in pre-dialysis chronic kidney disease. Nefrologia 39(1):18–28

    Article  Google Scholar 

  10. Bhan I, Dobens D, Tamez H et al (2015) Nutritional vitamin D supplementation in dialysis: a randomized trial. Clin J Am Soc Nephrol 10(4):611–619

    Article  CAS  Google Scholar 

  11. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO (2017) Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2017(7):1–59

    Google Scholar 

  12. Kidney Disease: Improving global outcomes (KDIGO) CKD-MBD working group (2009). KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113:S1–S130

  13. https://ridt.sinitaly.org/2017/03/18/2008-6/. Accessed 31 Jan 2021

  14. Shieh A, Ma C, Chun RF et al (2017) Effects of cholecalciferol vs calcifediol on total and free 25-hydroxyvitamin D and parathyroid hormone. J Clin Endocrinol Metab 102(4):1133–1140

    Article  Google Scholar 

  15. Scragg R, Stewart AW, Waayer D et al (2017) Effect of monthly high-dose vitamin d supplementation on cardiovascular disease in the vitamin D assessment study : a randomized clinical trial. JAMA Cardiol 2(6):608–616

    Article  Google Scholar 

  16. de Zeeuw D, Agarwal R, Amdahl M et al (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376(9752):1543–1551

    Article  Google Scholar 

  17. Stenvinkel PHC (2014) Cardiovascular disease in chronic kidney disease. In: Johnson RJ, Feehally J, Floege J (eds) Comprehensive clinical nephrology. Elsevier, Philadelphia, pp 949–966

    Google Scholar 

  18. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF (2012) Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 157(4):263–275

    Article  Google Scholar 

  19. Palmer SC, Di Micco L, Razavian M et al (2012) Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 156(6):445–459

    Article  Google Scholar 

  20. Manson JE, Cook NR, Lee IM et al (2019) Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med 380(1):33–44

    Article  CAS  Google Scholar 

  21. Scragg RKR (2019) Overview of results from the vitamin D assessment (ViDA) study. J Endocrinol Investig 42(12):1391–1399

  22. Eudra CT (2016) Natural vitamin D (cholecalciferol) versus standard care in patients receiving dialysis. https://doi.org/10.1186/ISRCTN15087616

  23. Tong A, Gill J, Budde K et al (2017) Toward establishing core outcome domains for trials in kidney transplantation: report of the standardized outcomes in nephrology-kidney transplantation consensus workshops. Transplantation 101(8):1887–1896

    Article  Google Scholar 

Download references

Acknowledgements

We acknowledge Dr. Boris Biclow for his support with the statistical analyses.

Mineral Metabolism Study Group of the Italian Society of Nephrology: Carlo Massimetti, Fabio Pennacchiotti, Antonio Mannarino, Cristina Grimaldi, Vincenzo Savica, Onofrio Schillaci, Olga Credentino, Maria Domenica Casu, Carlo Lomonte, Valentina Vigo, Giuseppe Grandaliano, Stefano Netti, Filippo Aucella, Massimo Morosetti, Roberto Boero, Francesco Soleti, Efstratios Fasianos, Maria Polidoro, Domenico Santoro, Alessandra Perna, Fabio Malberti, Ludovica d'Apice, Romano Musacchio, Maria Carla Porcu, Giuseppe Cianciolo, Silverio Rotondi e Maria Luisa Muci.

Funding

This work was a no-profit trial supported by the Italian Society of Nephrology. Grant/award number: not applicable.

Author information

Authors and Affiliations

Authors

Consortia

Contributions

Conception and design: LM, GS; data acquisition: LM, GC, AC, BDI, MDL, SM, AP; data analysis: AP; data interpretation: LM, SP, VS, AP, GS. Each author contributed important intellectual content during manuscript drafting or revision, accepts personal accountability for the author’s own contributions, and agrees to ensure that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

Corresponding author

Correspondence to Giovanni F. M. Strippoli.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Ethical approval

This study was performed in line with the principles of the Declaration of Helsinki. The study received Institutional Review Board approval from the Ethics Committee of the “Azienda Ospedaliera G. Rummo” of Benevento (deliberation n. 294, 13/04/2012).

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The members of the Mineral Metabolism Study Group of the Italian Society of Nephrology are listed in Acknowledgements.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 779 kb)

Supplementary file2 (DOCX 31 kb)

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morrone, L., Palmer, S.C., Saglimbene, V.M. et al. Calcifediol supplementation in adults on hemodialysis: a randomized controlled trial. J Nephrol 35, 517–525 (2022). https://doi.org/10.1007/s40620-021-01104-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40620-021-01104-z

Keywords

  • Calcifediol
  • Vitamin D
  • Hemodialysis
  • ESKD
  • Mortality